References

Artificial intelligence in thrombosis: transformative potential and emerging challenges

10.1186/s12959-025-00690-3 · 2025 · External reference

A systematic review of biomarkers for the prediction of thromboembolism in lung cancer - results, practical issues and proposed strategies for future risk prediction models

10.1016/j.thromres.2016.10.020 · 2016 · External reference

Dynamic thromboembolic risk modelling to target appropriate preventative strategies for patients with non-small cell lung cancer

10.3390/cancers11010050 · 2019 · External reference

Immune checkpoint inhibitors and venous thromboembolism: an analysis of the WHO pharmacovigilance database

10.1002/cpt.2615 · 2022 · External reference

A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the padua prediction score

10.1111/j.1538-7836.2010.04044.x · 2010 · External reference

The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma

10.1111/j.1538-7836.2004.00928.x · 2004 · External reference

Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study

10.1111/j.1538-7836.2006.01804.x · 2006 · External reference

Machine learning-based preoperative prediction of perioperative venous thromboembolism in Chinese lung cancer patients: a retrospective cohort study

10.3389/fonc.2025.1588817 · 2025 · External reference

Mutations in NSCLC and their link with lung cancer-associated thrombosis: a case-control study

10.1016/j.thromres.2013.10.042 · 2014 · External reference

Epidemiology and risk factors for venous thrombosis

10.1053/j.seminhematol.2007.02.004 · 2007 · External reference

Advances in the prediction and risk assessment of lung cancer-associated venous thromboembolism

10.2147/cmar.s328918 · 2021 · External reference

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

10.1002/14651858.cd008500.pub2 · 2012 · External reference

New data for venous thromboembolism in patients with small cell lung cancer: a review

10.1177/0268355517737670 · 2018 · External reference

Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: a prospective cohort study

10.1016/j.thromres.2019.12.009 · 2020 · External reference

Distinguishing tumor recurrence from radiation necrosis in treated glioblastoma using multiparametric MRI

10.1016/j.acra.2021.11.008 · 2022 · External reference

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

10.1002/ijc.31937 · 2019 · External reference

A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-Cancer-Associated thrombosis study

10.1634/theoncologist.2016-0414 · 2017 · External reference

Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: a systematic review and meta-analysis

10.1016/j.ctrv.2021.102280 · 2021 · External reference

Prevalence of venous thromboembolism in elective thoracic surgery

10.1016/j.arbres.2013.01.011 · 2013 · External reference

Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer

10.1016/j.jtcvs.2015.08.039 · 2016 · External reference

Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy

10.1016/j.thromres.2021.10.014 · 2021 · External reference

Predictors of venous thromboembolic events associated with central venous port insertion in cancer patients

10.1155/2014/743181 · 2014 · External reference

Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study

10.1186/s12885-020-06930-1 · 2020 · External reference

Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies

10.1200/jco.2010.32.3220 · 2011 · External reference

The incidence and predictors of thromboembolic events in patients with lung cancer

10.1155/2014/125706 · 2014 · External reference

Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy

10.1111/j.1538-7836.2007.02374.x · 2007 · External reference

Development and validation of a predictive model for chemotherapy-associated thrombosis

10.1182/blood-2007-10-116327 · 2008 · External reference

Predictors of venous thromboembolism and early mortality in lung cancer: results from a global prospective study (CANTARISK)

10.1634/theoncologist.2017-0205 · 2018 · External reference

Development and validation of a risk prediction model for venous thromboembolism in lung cancer patients using machine learning

10.3389/fcvm.2022.845210 · 2022 · External reference

Perioperative venous thromboembolism (VTE) prophalaxis in thoracic cancer patients: chinese experts consensus

10.3779/j.issn.1009-3419.2018.10.03 · 2018 · External reference

Risk factors associated with venous thromboembolic events in patients with malignancy

10.1097/01.mbc.0000224845.27378.c3 · 2006 · External reference

High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations

10.21037/tlcr-20-1290 · 2021 · External reference

Risk of thromboembolic events in cancer patients treated with immune checkpoint inhibitors: a meta-analysis of randomized controlled trials

10.1055/s-0042-1749185 · 2022 · External reference

Machine learning in the prediction of venous thromboembolism: systematic review and meta-analysis

10.2196/77339 · 2025 · External reference

Predictors of active cancer thromboembolic outcomes: validation of the khorana score among patients with lung cancer

10.1111/jth.13378 · 2016 · External reference

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

10.1182/blood.2020007878 · 2021 · External reference

High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis

10.1200/jco.2011.35.5669 · 2011 · External reference

The khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis

10.3324/haematol.2018.209114 · 2019 · External reference

Multicentre validation of the Geneva risk score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of thromboembolic RIsk and prophylaxis for medical PATients in SwitzErland (ESTIMATE)

10.1160/th13-05-0427 · 2014 · External reference

ROS1 gene rearrangements are associated with an elevated risk of peridiagnosis thromboembolic events

10.1016/j.jtho.2018.12.001 · 2019 · External reference

Validation of the khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy

10.1182/bloodadvances.2021006484 · 2022 · External reference

Risk of site-specific cancer in incident venous thromboembolism: a population-based study

10.1016/j.thromres.2014.12.013 · 2015 · External reference

Driver genes associated with the incidence of venous thromboembolism in patients with non-small-cell lung cancer: a systematic review and meta-analysis

10.3389/fonc.2021.680191 · 2021 · External reference

Intelligent predictive risk assessment and management of sarcopenia in chronic disease patients using machine learning and a web-based tool

10.1186/s40001-025-02606-3 · 2025 · External reference

Genomic structural equation modeling elucidates the shared genetic architecture of allergic disorders

10.1186/s12967-025-06465-8 · 2025 · External reference

Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients

10.1007/s12032-018-1120-9 · 2018 · External reference

Venous thromboembolism in patients diagnosed with lung cancer

10.1177/0003319715614945 · 2016 · External reference

Disorder of coagulation-fibrinolysis system: an emerging toxicity of Anti-PD-1/PD-L1 monoclonal antibodies

10.3390/jcm8060762 · 2019 · External reference

External validation of a venous thromboembolic risk score for cancer outpatients with solid tumors: the COMPASS-CAT venous thromboembolism risk assessment model

10.1634/theoncologist.2019-0482 · 2020 · External reference

Prospective assessment of clinical risk factors and biomarkers of hypercoagulability for the identification of patients with lung adenocarcinoma at risk for cancer-associated thrombosis: the observational ROADMAP-CAT study

10.1634/theoncologist.2017-0530 · 2018 · External reference

The khorana score for prediction of venous thromboembolism in cancer patients: an individual patient data meta-analysis

10.1111/jth.14824 · 2020 · External reference

Venous thromboembolism and lung cancer: a review

10.1186/s40248-015-0021-4 · 2015 · External reference

Value of assessment of pretest probability of deep-vein thrombosis in clinical management

10.1016/s0140-6736(97)08140-3 · 1997 · External reference

Optimal authoritative risk assessment score of Cancer-associated venous thromboembolism for hospitalized medical patients with lung cancer

10.1186/s12959-021-00339-x · 2021 · External reference

Risk factors and prediction models for venous thromboembolism in ambulatory patients with lung cancer

10.3390/healthcare9060778 · 2021 · External reference

Survival nomogram for stage IB non-small-cell lung cancer patients, based on the SEER database and an external validation cohort

10.1245/s10434-020-09362-0 · 2021 · External reference

Development and validation of a nomogram for predicting the 1-3-and 5-year survival in patients with acinar-Predominant lung adenocarcinoma

10.1007/s11596-022-2672-7 · 2022 · External reference

Deep learning-powered 3D segmentation derives factors associated with lymphovascular invasion and prognosis in clinical T1 stage non-small cell lung cancer

10.1016/j.heliyon.2023.e15147 · 2023 · External reference